Marriott International (MAR) is currently trading at $369.80. Based on 24 Wall Street analysts, the average target price is $384.83, implying a 4.1% upside. The consensus recommendation is BUY.

MAR

Marriott International

Consumer DiscretionaryOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$369.80

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$353.00$449.00
Current $369.80
Median: $384.00Mean: $389.82Current: $369.80

Recent price target updates (latest 80)

  • JP MorganJul 21, 2026

    PT action: Raises

    $387.00 → $400.00

  • TD CowenJul 21, 2026

    PT action: Raises

    $410.00 → $420.00

  • BarclaysJul 21, 2026

    PT action: Raises

    $376.00 → $379.00

  • Morgan StanleyJul 17, 2026

    PT action: Raises

    $353.00 → $380.00

  • StifelJul 17, 2026

    PT action: Raises

    $352.00 → $365.00

  • Wells FargoJul 16, 2026

    PT action: Raises

    $446.00 → $449.00

  • MacquarieJul 14, 2026

    PT action: Raises

    $354.00 → $365.00

  • UBSJun 15, 2026

    PT action: Raises

    $336.00 → $412.00

  • Truist SecuritiesMay 26, 2026

    PT action: Raises

    $350.00 → $356.00

  • BernsteinMay 15, 2026

    PT action: Raises

    $400.00 → $402.00

  • Morgan StanleyMay 12, 2026

    PT action: Raises

    $350.00 → $353.00

  • MacquarieMay 7, 2026

    PT action: Raises

    $350.00 → $354.00

  • BarclaysMay 7, 2026

    PT action: Raises

    $372.00 → $376.00

  • Wells FargoMay 7, 2026

    PT action: Raises

    $443.00 → $446.00

  • MizuhoMay 7, 2026

    PT action: Raises

    $343.00 → $384.00

  • BairdMay 7, 2026

    PT action: Lowers

    $388.00 → $386.00

  • Evercore ISI GroupApr 24, 2026

    PT action: Raises

    $385.00 → $400.00

  • SusquehannaApr 23, 2026

    PT action: Raises

    $280.00 → $385.00

  • JP MorganApr 21, 2026

    PT action: Raises

    $356.00 → $383.00

  • BarclaysApr 16, 2026

    PT action: Raises

    $356.00 → $372.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$384.83

Based on 24 analysts

Analyst Recommendations

Buy (12)Hold (12)Sell (2)

Upside

+4.07%

Market Cap

$0.00B

Financial & Investment Metrics

P/E Ratio (TTM)38.68
Forward P/E28.20
P/B RatioN/A
Dividend Yield0.79%
Return on Equity (ROE)N/A
Operating Margin59.01%
Debt to EquityN/A
Beta (Volatility)1.11
52 Week Range$253.76 - $410.98
LowCurrent: $369.80High

Latest News

Daily editorial mentioning MAR

Price target moves

BMO Capital Lifts GOOGL and BLK Targets Amidst Broad NFLX Revisions

As of July 20, 2026, the analyst community has been busy recalibrating expectations across key S&P 500 constituents. Most notably, BMO Capital initiated a series of adjustments on July 17, pushing their target for Alphabet (GOOGL) to $455 from $435, while simultaneously raising BlackRock (BLK) to $1300 from $1250.

Revisions this week

The activity was concentrated in the financial and healthcare sectors. Morgan Stanley (MS) saw upward adjustments from both BMO Capital (to $250) and Freedom Broker (to $245), highlighting a firming sentiment toward the banking giant. Healthcare also saw significant movement; UnitedHealth Group (UNH) captured upgrades from Morgan Stanley to $529 and Keybanc to $500.

Conversely, the downward revisions were marked by a heavy concentration in Communication Services. Netflix (NFLX) faced a barrage of target cuts from five different firms, including Goldman Sachs, JP Morgan, and Morgan Stanley, with price targets coalescing around the $83–$94 range.

Ticker Firm Dir Prior→Current
GOOGL BMO Capital Up 435→455
NFLX JP Morgan Down 118→85
ISRG Piper Sandler Down 580→470
MS BMO Capital Up 240→250

What to notice

The divergence in Healthcare targets is particularly striking. While Piper Sandler and Raymond James took a sharper stance on Intuitive Surgical (ISRG), slashing targets to $470 and $483 respectively, other corners of the sector like Elevance Health (ELV) saw Leerink Partners boost their target to $395. This suggests that while broader sector sentiment remains generally positive, specific valuation models for surgical robotics are undergoing a more aggressive reset. You can track these shifting consensus trends on our dedicated moves page.

Sector divergence in tech and energy

The IT and energy sectors saw individual, albeit significant, downward revisions that bucked the broader positive momentum seen in financials. Citigroup’s decision to drop IBM from $375 to $255 represents a substantial recalibration, signaling a move to align with more conservative valuation multiples. Similarly, the energy space saw Occidental Petroleum (OXY) pared back to $60 by Citigroup, reflecting a cooling outlook on price appreciation for the firm relative to its historical consensus.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 0

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Frequently Asked Questions

Q. What is the current target price and upside for MAR?

A. The current target price for Marriott International is $384.83, which implies a 4.1% upside from the current price of $369.80. This is based on the consensus of 24 Wall Street analysts.

Q. What is the current analyst recommendation for MAR?

A. Currently, there are 1 Strong Buy, 11 Buy, 12 Hold, 1 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying MAR stock recently?

A. Over the past 6 months, there have been 0 insider buys and 0 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Consumer Discretionary

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer